← Back to guidelines
Oncology9 papers

Nonkeratinizing carcinoma of the nasopharynx

Last edited: 4/10/2026

Overview

Nasopharyngeal carcinoma (NPC) is a distinct malignancy within head and neck cancers, differing in its biology, epidemiology, histology, natural history, and treatment response 1. Nonkeratinizing histology is common in NPC 1.

Diagnosis

  • Diagnosis is based on clinical presentation, imaging, and biopsy 1.
  • Management

  • Radiotherapy (RT) is the cornerstone of locoregional treatment for non-disseminated disease 1.
  • Combination of chemotherapy with RT improves survival rates 1.
  • For metastatic disease, treatment involves platinum/gemcitabine-based chemotherapy, which can lead to long survival times 1.
  • Key Recommendations

  • Radiotherapy is the cornerstone of locoregional treatment for non-disseminated nasopharyngeal carcinoma 1. (Evidence: Moderate)
  • Combining chemotherapy with radiotherapy improves survival rates for nasopharyngeal carcinoma 1. (Evidence: Moderate)
  • Platinum/gemcitabine-based chemotherapy is indicated for metastatic nasopharyngeal carcinoma 1. (Evidence: Moderate)
  • References

    1 Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B et al.. SEOM-TTCC clinical guideline in nasopharynx cancer (2021). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2022. link

    Original source

    1. [1]
      SEOM-TTCC clinical guideline in nasopharynx cancer (2021).Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG